Literature DB >> 6723768

Bioavailability of cyclophosphamide from oral formulations.

T Wagner, K Fenneberg.   

Abstract

Cyclophosphamide (CP) is an alkylating cytostatic compound, which is activated to its cytotoxic form in the liver [1]. Since the therapeutic range of CP in the treatment of human tumours, is small like other cytostatics, a constant high bioavailability is essential for its oral administration. Although CP has become one of the most widely used cytostatics [2], there do not appear to have been any bioavailability investigations providing the necessary information. The development of a very sensitive gas chromatographic analytical method has now permitted investigation of the pharmacokinetics of oral CP in conventional clinical doses [3, 4, 5, 6].

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6723768     DOI: 10.1007/BF00630298

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  3 in total

1.  Decreased half life of cyclophosphamide in patients under continual treatment.

Authors:  M D'Incalci; G Bolis; T Facchinetti; C Mangioni; L Morasca; P Morazzoni; M Salmona
Journal:  Eur J Cancer       Date:  1979-01       Impact factor: 9.162

2.  Pharmacokinetics of cyclophosphamide and alkylating activity in man after intravenous and oral administration.

Authors:  F D Juma; H J Rogers; J R Trounce
Journal:  Br J Clin Pharmacol       Date:  1979-09       Impact factor: 4.335

3.  Pharmacokinetics of the cytostatic drugs used in the CMF-regimen.

Authors:  P H Slee; E A de Bruijn; O M Driessen; J Hermans; A T van Oosterom
Journal:  Anticancer Res       Date:  1983 Jul-Aug       Impact factor: 2.480

  3 in total
  3 in total

1.  Pharmacokinetics of intravenous and oral cyclophosphamide in the presence of methotrexate and fluorouracil.

Authors:  E A De Bruijn; P H Slee; A T Van Oosterom; D W Lameijer; K J Roozendaal; U R Tjaden
Journal:  Pharm Weekbl Sci       Date:  1988-10-14

Review 2.  Ifosfamide clinical pharmacokinetics.

Authors:  T Wagner
Journal:  Clin Pharmacokinet       Date:  1994-06       Impact factor: 6.447

3.  Randomized comparison of etoposide pharmacokinetics after oral etoposide phosphate and oral etoposide.

Authors:  R S de Jong; N H Mulder; D R Uges; S Kaul; B Winograd; H J Groen; P H Willemse; W T van der Graaf; E G de Vries
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.